SCP Vitalife

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

Ivenix is a medical technology company that develops a next-generation infusion management system. It is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow. The company was founded in 2007 and is headquartered in Amesbury, Massachusetts.

Medical Surgery Technologies (MST) was founded in 2005 by Ziv Tamir and Moti Sholev, entrepreneurs with extensive experience in medical devices. MST leads the field of surgical analytics with its core image analytics technology designed to empower and automate the surgical environment, with a focus on medical robotics and computer-assisted surgery (MRCAS). The company's core technology is a software-based image analytics information platform powered by advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics. The platform is positioned to enable the operating room of the future through real-time image analytics, connectivity and automation, providing value-added functionality for surgeon, provider and patient. MST’s initial offering is AutoLap™, the only robotic image-guided laparoscope positioning system. Powered by MST’s image-analysis software, AutoLap™ interacts with the surgeon’s movements in the surgical cavity, guiding the robotic laparoscope positioner in real time, offering the surgeon full and natural control of the surgical procedure and an optimal field of view.

Sensible Medical Innovation Ltd. is introducing a breakthrough sensing and monitoring technology providing actionable and accurate data for guiding the management and treatment of several chronic medical conditions representing today’s biggest burden on US and worldwide healthcare budgets.

Lifeward develops, manufactures, and markets a walking system for persons with lower limb disabilities Its products include ReWalk Rehabilitation System and ReWalk Personal System. ReWalk Rehabilitation System allows walking, standing, sitting, and the capacity to ascend or descend stairs in the rehab center environment. The ReWalk Personal System is designed for everyday use in a range of environments. It can be used at home, work, or other locations and it functions outdoors and on different surfaces or terrains. The ReWalk Personal System allows sitting, standing, and turning as well as offers the ability to climb and descend stairs. The company changes the quality of life for individuals with lower limb disability by developing robotic technologies. Rewalk Robotics was founded on 2001 and is based in Marlborough, Massachusetts.

Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the United States, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States.

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the United States, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States.

Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.

Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the United States, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States.

novoGI™ (previously NiTi Surgical Solutions) is committed to advancing patient care by providing an expanding range of comprehensive solutions for GI disease management. NiTi Surgical Solutions has developed the first major advance in closure for gastrointestinal surgery in more than 30 years. NiTi's proprietary technology represents a breakthrough in natural healing with tissue-sparing, uniform BioDynamix anastomosis. The company's unique line of products utilizes Nitinol-based elements to press together the ends of resected tissue, enabling a natural reconnection of the intestine after removing a section, for example, as part of a colon cancer treatment. The company is commercializing a family of FDA-cleared and CE-marked disposable tissue closure devices.

Garnet BioTherapeutics is a clinical stage, venture-backed cell therapy company focused on dermal-based regenerative therapy.

Sightline Technologies Ltd. provides medical products and services. The Company designs, develops, and markets a colonoscope with a disposable tube and sheath, which is used for diagnosing and treating abnormalities in the large intestine. Sightline Technologies primarily operates in Israel.

Beta-O2 Technologies Ltd. is a biomedical company, developing a proprietary implantable bioreactor, the ßAir, for the treatment of patients with type 1diabetes (T1D). ßAir was developed to address the main problems of the otherwise successful procedure in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and deterioration of functionality the transplanted islets over time due to insufficient oxygen supply. It is a small medical device, which is implanted in a minimally invasive procedure. The islet-cell-containing device is planned to provide patients with freedom from insulin injections and repeated monitoring of glucose levels. This innovative device also reduces the risk for hypoglycemic episodes as well as diabetes complications. ßAir provides very effective protection from the host immune system, thus eliminating the need for immunosuppressive therapy and preventing what could otherwise be a fatal immune response of the patient to the transplanted cells.

GeneGrafts Ltd. is a biotechnology company developing proprietary technology for modulating excitable tissues, such as of brain or heart, by cell therapy. This new paradigm can be used for treatment of various diseases including Parkinson's disease and other neurological disorders or cardiac arrhythmias. They have developed a novel technology platform based on transplantation of cell grafts, isolated from the patient's own body, which defines the ion channels. These grafted cells integrate functionally and structurally with the target organ, and their electrical properties are derived from the expressed ion channels. The electrical properties of target organ are modulated in a predetermined way. This technology is designed for treatment of neurological disorders and cardiac arrhythmias.

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.